Icellator® X Delivers Results in First Clinical Application

High Acceptance of Advanced Healthcare Equipment Promoting Growth of a-Si X-ray Flat Panel Detectors | Fact.MR’s Medtech Analysis

Big data and analytics will drive patient outcomes in a big way, and the coming years will witness a growing emphasis on healthcare service providers in the business of gathering and processing patient health data.

KA Imaging Makes Distribution Deal with Malaysia Based BeyMed

BeyMed is an emerging medical solutions company with a great potential,” said Amol Karnick, President and CEO of KA Imaging.

BASMA.com Raises a $3M Series a Round to Scale Up Its Health Tech Platform in the MENA

The UK-based, MENA focused, startup BASMA.com closed $3M in its Series A round of funding led by MEVP with the participation of SOSF, IM capital and returning investors iSME, Cedar Mundi Ventures and IFA capital.

Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than had been previously possible.

The patients received stem cell therapy at the Okyanos clinic for conditions such as Parkinson’s disease, osteoarthritis, fibromyalgia and rheumatoid arthritis. In each case, Icellator X derived more than 100 million regenerative cells from the patients’ own adipose or fat tissue obtained through liposuction to treat their conditions. This higher yield of cells is important as it has the potential to produce more reliable and reproducible results for patients.

“Launching this next generation device marks a major milestone for our company,” said Ben Chlebina, General Manager, Tissue Genesis. “We are now focusing on expanding the Icellator X into our clinical programs across the United States, as well as launching of our clinical and commercial efforts globally.”

The Icellator X features a user-friendly touchscreen interface that is adaptable to multiple languages. With its single-use disposable treatment kit to ensure sterility and a patient’s own fat tissue, it generates an enzyme-derived stromal vascular fraction (SVF) therapeutic product through a process which takes approximately one hour.

“The Tissue Genesis team designed the Icellator X to become the gold standard in automated stem cell isolation,” said Dr. Rolf Wolters, Director of Product Management, Tissue Genesis. “We incorporated advanced hardware and software technologies to significantly boost Icellator X’s performance over our first-generation, industry-leading Icellator model.”

Patients at the Okyanos clinic received treatments from Icellator X machines on site. More patients are scheduled for treatment at the clinic using the Icellator X in the coming weeks.

“Our clinical team at Okyanos found the Icellator X to be simple to use and highly efficient,” said Dr. Vincent Burton, President, Chief Medical Officer and Chief Anesthesiologist, Okyanos Center for Regenerative Medicine. “The high yield of target cells is extraordinary and will ultimately deliver better outcomes for our patients who suffer with neurologic, orthopedic and autoimmune conditions.”

Tissue Genesis is a Houston-based company providing enzyme-derived autologous cell therapy processing solutions using high-performance, point-of-care technology to extract adult stem cells from adipose tissue.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles